Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting

PURPOSE: EGFR tyrosine kinase inhibitor (TKI) therapy in EGFR-mutated lung cancer is limited by acquired resistance. In half of the patients treated with first/second-generation (1st/2nd gen) TKI, resistance is associated with EGFR p.T790M mutation. Sequential treatment with osimertinib is highly ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraskowski, Oliver, Stratmann, Jan A., Wiesweg, Marcel, Eberhardt, Wilfried, Metzenmacher, Martin, Schmid, Kurt W., Herold, Thomas, Schildhaus, Hans-Ulrich, Darwiche, Kaid, Aigner, Clemens, Stuschke, Martin, Laue, Katharina, Zaun, Gregor, Kasper, Stefan, Hense, Jörg, Sebastian, Martin, Schuler, Martin, Pogorzelski, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374675/
https://www.ncbi.nlm.nih.gov/pubmed/37198447
http://dx.doi.org/10.1007/s00432-023-04839-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374675/
https://www.ncbi.nlm.nih.gov/pubmed/37198447
http://dx.doi.org/10.1007/s00432-023-04839-3

Ejemplares similares